Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | THRB | P10828 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | THRA | P10827 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.44 |
| ▸ | MPI | P34949 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28005538 | 0.90 | GLA (0.69) | GLASMN1; SMN2RAB9AALDH1A1MAPT | |
| SCHEMBL8524267 | 0.87 | THRB (0.53) | GLASMN1; SMN2RAB9AALDH1A1MAPT | |
| SCHEMBL14002787 | 0.86 | GLA (0.60) | GLASMN1; SMN2RAB9AALDH1A1MAPT | |
| Water SCHEMBL27813121 | 0.86 | THRB (0.52) | GLASMN1; SMN2RAB9AALDH1A1MAPT | |
| SCHEMBL15475535 | 0.80 | GLA (0.58) | GLASMN1; SMN2RAB9AALDH1A1MAPT | |
| SCHEMBL15475537 | 0.80 | GLA (0.58) | GLASMN1; SMN2RAB9AALDH1A1MAPT | |
| SCHEMBL12897872 | 0.79 | PAOX (0.54) | GLAALDH1A1MAPTKMT2ATHRB | |
| SCHEMBL28191332 | 0.79 | TSHR (0.56) | SMN1; SMN2MAPTPOLBKMT2ALMNA | |
| SCHEMBL1286679 | 0.78 | GLA (0.64) | GLASMN1; SMN2RAB9AALDH1A1MAPT | |
| Bromide SCHEMBL30245626 | 0.77 | GLA (0.58) | GLASMN1; SMN2ALDH1A1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210244736-A1 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | MERCK PATENT GMBH (DE) | 2021-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210244736-A1 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | BTK, SYK, LCK | GLA 2791/4885SMN1; SMN2 4593/4885RAB9A 2813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.